The Burden of Proof.

In 2023, ProPublica and The Capitol Forum published internal Cigna documents describing a review system called PXDX, under which company doctors could deny batches of claims without opening the patient files. Over two months in 2022, the system was used to deny 300,000 claims — an average of 1.2 seconds of review per claim. Cigna told reporters the process was legal and applied to low-cost claims. That defence is worth sitting with: the proving apparatus pointed at families operates in seconds when pointed by the payer.

For autism specifically, ProPublica’s 2024 reporting on UnitedHealth Group’s Optum unit described internal strategy documents for limiting spending on applied behavior analysis — the most commonly prescribed autism therapy — in the Medicaid plans it manages. The documents describe applying a “more rigorous” clinical review to ABA in roughly 20 states, culling providers from the network, and authorizing fewer therapy hours than clinicians requested — while the company projected spending about $290 million on ABA in its Medicaid plans that year, and its parent reported $22 billion in annual net profit. A related Optum program for limiting outpatient therapy was ruled unlawful by courts or regulators in three states, per the same reporting.

None of this machinery is confined to one company. The American Medical Association’s 2024 survey found practices completing 39 prior-authorization requests per physician per week, with 93% of physicians reporting that prior authorization delays necessary care. When federal inspectors audited Medicare Advantage prior-authorization denials for post-acute care, they found 95% of appealed nursing-facility denials were overturned. And the federal agencies that police mental-health parity reported to Congress in 2026 that the most common violation remains exactly the one autism families know best: stricter prior authorization and utilization review for behavioral care than for medical care.

The denial statistics in Part II describe paperwork. This is what the paperwork does to a childhood. In a cohort of 4,145 children referred for ABA inside a single large US health system, researchers followed what happened next: 13% never received any ABA at all, 66% were still in therapy at twelve months, 46% at twenty-four, and 28% received the full clinically recommended dose — the dose the evidence base for the therapy is actually built on. A separate study of a different Kaiser region found 23% of referred children never initiated treatment, and that only 15% received at least 80% of their recommended hours.

The second clock starts earlier and runs longer. Autism can be identified far sooner than it usually is: Pierce and colleagues found that a diagnosis made at around 14 months is already largely stable, with stability rising through the second year. The median American child is diagnosed at 47 months. Then, in the publicly funded systems studied by Yingling and colleagues, an average of nearly three more years passes between diagnosis and the start of intensive intervention.

Put those together and the child who could have started at eighteen months frequently starts near seven. That interval is not neutral waiting; it is the interval the clinical evidence identifies as the one that matters most. The Early Start Denver Model trial recorded a 17.6-point IQ gain against 7.0 in the comparison group for toddlers starting between 18 and 30 months, and a later cost analysis of the same model found it cost about $14,000 more per year while it ran and saved roughly $19,000 per child per year afterwards. The system is not only failing the child. It is declining a return it has already been shown.

Autism coverage in the United States was not granted; it was extracted. Beginning with Indiana in 2001 and ending with Tennessee in 2019, every state and the District of Columbia eventually passed a law forcing insurers to cover autism services — a state-by-state campaign fought over eighteen years against the documented opposition of the industry’s trade association. AHIP’s public argument — that mandates raise premiums and thereby “reduce access to affordable coverage” — reframed paying for disabled children’s therapy as a threat to everyone else’s insurance.

The industry’s weapon in those fights was the cost projection, and the record now lets us score them. In Oklahoma in 2009, an actuary retained for House leadership warned legislators that the proposed mandate, “Nick’s Law,” would raise premiums by 7.8% to 19.8%; the state’s own employee insurance board put it at 1% or less, and the bill died in committee. The peer-reviewed estimate published that same year by Bouder, Spielman and Mandell landed at about 1%, with an upper bound of 2.31%. The insurer-side figure was high by roughly an order of magnitude, and it worked anyway: Oklahoma parents later filed a professional-conduct complaint over the analysis.

What the mandates actually cost is now measurable. Across state-employee plans the reported cost of adding autism coverage was $0.15 per member per month in the first year and $0.31 in the second — figures collected by Autism Speaks, an advocacy organization, and reported in the Harvard Law & Policy Review, so worth treating as directional rather than independent actuarial work. The independent confirmation is Pennsylvania’s: after its mandate, actual autism-related spending came to $6,289 per child in 2012 — 17% of the $36,000 annual cap insurers had warned about. Meanwhile the peer-reviewed evaluations found exactly what compulsion was supposed to achieve: treated prevalence rose, service use and spending per child increased, and the board-certified behaviour-analyst workforce grew from 1.34 to 29.88 per 100,000 children between 2003 and 2017.

There is a catch that makes the entire mandate story narrower than it sounds. State insurance mandates do not reach self-funded employer plans, which are governed by the federal ERISA statute instead. In 2025, 67% of covered US workers — and 80% of those at large firms — were in exactly such plans. The hardest-won consumer protection in autism coverage does not legally apply to two-thirds of the people who assume it protects them.

The lobbying that defends this architecture is a line item. In 2024 the insurance industry spent approximately $155 million on federal lobbying — one industry, one year, one country. The Affordable Care Act’s medical-loss-ratio rules cap what insurers may retain at 15–20% of premium for administration and profit; on the industry’s scale that retained share is measured in hundreds of billions. A company the size of UnitedHealth Group — $447.6 billion in 2025 revenues — does not need to deny any individual claim in bad faith for the arithmetic to work. It needs only a system in which proving is slow, appealing is rare, and the default is no.

The lobbying that defends this architecture is a line item. In 2024 the insurance industry spent approximately $155 million on federal lobbying — one industry, one year, one country. The Affordable Care Act’s medical-loss-ratio rules cap what insurers may retain at 15–20% of premium for administration and profit; on the industry’s scale that retained share is measured in hundreds of billions. A company the size of UnitedHealth Group — $447.6 billion in 2025 revenues — does not need to deny any individual claim in bad faith for the arithmetic to work. It needs only a system in which proving is slow, appealing is rare, and the default is no.

Canadians read the American material in Parts I–IV with a comfortable distance that the record does not support. The Canada Health Act guarantees universality only for medically necessary hospital and physician services; in Auton (2004), the Supreme Court of Canada held that ABA/IBI therapy for autistic children sits outside that protected core. Autism therapy in Canada is therefore not covered by medicare’s logic — each province builds its own program, and Ontario built one that borrows the insurer’s architecture.

Consider the Ontario Autism Program as a parent meets it. You register through AccessOAP, a privately operated intake administrator paid roughly $57.9 million a year. You wait — 69,166registered children currently do, a number that has grown from the 1,700 the Auditor General counted waiting in 2013 and the 27,600 the Financial Accountability Office documented in 2020. When your invitation arrives, a care coordinator determines your child’s “support needs and funding” — a determination, like an adjuster’s. Funding arrives as an individual allocation between $6,600–$65,000/year, and you must document how it is spent and keep receipts for seven years for reconciliation. Register, wait, prove, submit, reconcile: the grammar of a claim, not of an entitlement.

The clinical stakes of that grammar are established in the same literature that justifies early intervention: in the first randomized controlled trial of comprehensive early intervention, toddlers who started therapy gained 17.6 IQ points over two years versus 7.0 in the comparison group. UK survey data put the average delay from first professional contact to autism diagnosis at about three and a half years — and in Ontario the diagnosis is only the ticket to the queue. The province currently budgets $965M for the program against the $1.35B the FAO’s methodology implies is needed — a $385M annual gap that the waiting list absorbs. A burden-of-proof system does not have to deny anyone; the queue denies by delay, and the delay lands inside the developmental window that the evidence says matters most.